MedWatch

Novo Nordisk launches oral semaglutide in India

Novo Nordisk’s diabetes drug, semaglutide, will be sold in the country in a similar price range as its injectable version.

Photo: Novo Nordisk / PR

On Thursday, Novo Nordisk announced that its diabetes drug semaglutide will be launched as a pill in India, as reported by media the Economic Times.

This will be the sixth country where oral semaglutide has been launched commercially.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs